United Therapeutics Co. (NASDAQ:UTHR) Shares Acquired by Soleus Capital Management L.P.

Soleus Capital Management L.P. increased its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 7.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 109,394 shares of the biotechnology company's stock after acquiring an additional 7,500 shares during the period. United Therapeutics makes up 2.4% of Soleus Capital Management L.P.'s investment portfolio, making the stock its 13th largest position. Soleus Capital Management L.P. owned about 0.25% of United Therapeutics worth $38,599,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of the stock. Wealthfront Advisers LLC lifted its position in United Therapeutics by 2,090,573.5% during the fourth quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company's stock valued at $6,462,018,000 after buying an additional 18,313,424 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of United Therapeutics by 0.7% during the fourth quarter. Vanguard Group Inc. now owns 4,441,823 shares of the biotechnology company's stock valued at $1,567,253,000 after purchasing an additional 32,213 shares during the period. FMR LLC raised its stake in shares of United Therapeutics by 36.5% during the fourth quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company's stock valued at $519,170,000 after purchasing an additional 393,777 shares during the period. Geode Capital Management LLC raised its stake in shares of United Therapeutics by 4.0% during the fourth quarter. Geode Capital Management LLC now owns 1,138,292 shares of the biotechnology company's stock valued at $401,184,000 after purchasing an additional 44,277 shares during the period. Finally, AQR Capital Management LLC raised its stake in shares of United Therapeutics by 0.8% during the fourth quarter. AQR Capital Management LLC now owns 975,444 shares of the biotechnology company's stock valued at $344,176,000 after purchasing an additional 7,710 shares during the period. 94.08% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 11,000 shares of the business's stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $300.93, for a total transaction of $3,310,230.00. Following the completion of the sale, the executive vice president now owns 36,781 shares in the company, valued at $11,068,506.33. The trade was a 23.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Michael Benkowitz sold 10,000 shares of the business's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $360.76, for a total transaction of $3,607,600.00. Following the sale, the chief operating officer now owns 2,577 shares of the company's stock, valued at approximately $929,678.52. The trade was a 79.51% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 55,500 shares of company stock worth $17,054,780 over the last 90 days. Insiders own 10.30% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Morgan Stanley lifted their price objective on shares of United Therapeutics from $346.00 to $348.00 and gave the company an "equal weight" rating in a research note on Thursday, May 1st. Bank of America upgraded shares of United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 price objective on the stock in a research note on Monday, April 21st. Wall Street Zen lowered shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 2nd. JPMorgan Chase & Co. dropped their price objective on shares of United Therapeutics from $355.00 to $350.00 and set an "overweight" rating on the stock in a research note on Thursday, May 1st. Finally, Wells Fargo & Company reiterated an "equal weight" rating and set a $314.00 price objective (down previously from $395.00) on shares of United Therapeutics in a research note on Friday, April 25th. Four investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $392.00.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR traded down $1.07 during midday trading on Friday, reaching $307.65. The company had a trading volume of 269,594 shares, compared to its average volume of 442,590. The stock's fifty day moving average price is $299.63 and its 200-day moving average price is $338.32. The stock has a market capitalization of $13.88 billion, a P/E ratio of 13.51, a PEG ratio of 0.97 and a beta of 0.58. United Therapeutics Co. has a one year low of $264.33 and a one year high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, beating the consensus estimate of $6.29 by $0.34. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm had revenue of $794.40 million during the quarter, compared to analyst estimates of $726.82 million. During the same quarter in the previous year, the firm earned $6.17 earnings per share. The firm's revenue for the quarter was up 17.2% compared to the same quarter last year. As a group, sell-side analysts forecast that United Therapeutics Co. will post 24.48 earnings per share for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.